FDA Issues Warning Letter to Lupin Pharmaceuticals

Drug GMP Report
Lupin products manufactured at its Mandideep, India, facility were cited for multiple GMP violations in a recent FDA warning letter.
Correction: The July 2009 issue of Drug GMP Report incorrectly reported that products manufactured at Lupin Pharmaceuticals’ Mandideep facility in India were placed under an import alert after receiving a warning letter from the FDA. The facility did receive a warning letter for several GMP violations but no import alert was issued. FDAnews regrets the error.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $20.00